Publisher Summary Hepatocellular carcinomas (HCC) are among the most common
malignancies in the world with tumor incidence approaching 150 per 100,000 per year in …

Mechanistic studies with phenobarbital (PB), 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)
and other liver tumor promoters support a general model of promotion involving negative …

Phenobarbital was the first tumor promoter for rodent liver to be associated with the 2-stage
or initiation-promotion concept of carcinogenesis. In rats and mice preinitiated with …

Foci of altered hepatocytes are preneoplastic lesions capable of progressing to
hepatocellular carcinomas. To Characterize the growth of preneoplastic hepatic lesions, size …

A number of different compounds appears to promote the development of liver tumors from
previously induced initiated cells. These compounds include phenobarbital, hypolipidemic …

Chronic exposure to high doses of phenobarbital (PB) causes hepatocellular adenomas in
both mice and rats and hepatocellular carcinomas in some strains of mice. Long-term PB …

One of the many hypotheses put forward to explain the mechanism by which phenobarbital
(PB) promotes hepatocarcinogenesis is by differential mitoinhibition of surrounding …

One of the proposed mechanisms by which phenobarbital (PB) promotes
hepatocarcinogenesis in the rat is by differential mitoinhibition. However, our earlier studies …

The significance of the development of nodular liver lesions in rodents following the
administration of test agents raises several questions which could be placed in one of two …

Phenobarbital (PB), a non-genotoxic hepatocarcinogen in rodents, has been studied
extensively but its mechanism of carcinogenic action is unclear. PB appears to function as a …